Bellevue Group Ag Macrogenics Inc Transaction History
Bellevue Group Ag
- $5.02 Billion
- Q4 2024
A detailed history of Bellevue Group Ag transactions in Macrogenics Inc stock. As of the latest transaction made, Bellevue Group Ag holds 9,929,963 shares of MGNX stock, worth $23 Million. This represents 0.64% of its overall portfolio holdings.
Number of Shares
9,929,963
Previous 9,929,963
-0.0%
Holding current value
$23 Million
Previous $32.7 Million
1.22%
% of portfolio
0.64%
Previous 0.55%
Shares
27 transactions
Others Institutions Holding MGNX
# of Institutions
131Shares Held
56MCall Options Held
28.3KPut Options Held
197K-
Armistice Capital, LLC New York, NY6.28MShares$14.6 Million0.29% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$12.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.32MShares$10 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.49MShares$8.09 Million0.06% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.18MShares$7.37 Million0.62% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $143M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...